PTC Therapeutics, Inc. (PTCT) Monday said that the European Commission has granted marketing authorization for Sephience for the treatment of phenylketonuria (PKU).
The company noted that the uthorization includes a broad label inclusive of all ages and disease severities.
The approval is based on results from the Phase 3 APHENITY study as well as evidence of durable treatment effect and the ability of study participants to liberalize their diet in the APHENITY long-term extension study.
The European launch of Sephience will be initiated in Germany in the first half of July.
The company has submitted a new drug application (NDA) for Sephience to the FDA, which the regulator is expected to decide on July 29 this year. The drug is under review in several other countries including Japan and Brazil.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.